Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Short term Debt (2021 - 2025)

Journey Medical (DERM) has disclosed Short term Debt for 4 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt changed N/A year-over-year to $5.6 million, compared with a TTM value of $5.6 million through Sep 2025, changed N/A, and an annual FY2022 reading of $2.9 million, up 263.05% over the prior year.
  • Short term Debt was $5.6 million for Q3 2025 at Journey Medical, up from $3.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $9.9 million in Q2 2023 and bottomed at $812000.0 in Q4 2021.
  • Average Short term Debt over 4 years is $4.0 million, with a median of $3.0 million recorded in 2023.
  • Peak annual rise in Short term Debt hit 263.05% in 2022, while the deepest fall reached 263.05% in 2022.
  • Year by year, Short term Debt stood at $812000.0 in 2021, then surged by 263.05% to $2.9 million in 2022, then soared by 237.25% to $9.9 million in 2023, then plummeted by 43.42% to $5.6 million in 2025.
  • Business Quant data shows Short term Debt for DERM at $5.6 million in Q3 2025, $3.8 million in Q2 2025, and $1.9 million in Q1 2025.